Khiron Life Sciences Corp. announced the receipt of the Company's ever shipment of EU-GMP certified medical cannabis product for distribution and sale into the German market. Recently, Khiron's German distribution partner, Nimbus Health GmbH, received approximately 36kg of Khiron 20/1 medical cannabis product, a THC-dominant cannabis flower product which has been prescribed to patients in the UK since July 2020. The new product increases the Company's German medical cannabis offering, which now includes both THC-dominant and CBD-dominant Cannabis products. As a result of the shipment, the Company expects to increase its European medical cannabis sales in the second quarter of 2021. Khiron's European product portfolio now includes both THC-dominant and CBD-dominant cannabis flower products available for sale in Germany and the UK, two of the chronic pain markets in Europe. Over the coming months, the Company plans to increase patient access by expanding its product offering and medical education initiatives.